Welcome! Login | Register
 

Matt Light Announces Charity Event Related to Deflategate—Matt Light recently announced a fundraising campaign

ACLU of RI Files Lawsuit That Challenges 106-Year-Old Statute—The ACLU of Rhode Island filed a federal…

Councilman Hassett to Address Property Issues in Providence Neighborhood—Councilman Terrence M. Hassett (Ward Twelve) released a…

Providence Ranked 4th Most LGBT-Friendly City in U.S.—Providence, RI is the fourth most LGBT-friendly city…

FBI Charges Top FIFA Execs - What Does This Mean for Soccer?—In events that are still unfolding, nine FIFA…

Should the Red Sox Look to Pawtucket For Improvements?—The Red Sox should look to their Triple-A…

Brown’s Hazeltine to be Inducted into RI Entrepreneurship Hall of Fame—The Met School’s Center for Innovation and Entrepreneurship…

Giannini: Hot Topics of 2015 at the General Assembly—‏One hot topic of the General Assembly this…

Matt Fecteau: Is RI Dem Chair McNamara Captain of the Titanic?—Growing up, my father constantly used the master…

It’s All About Education: The Arts, Education, and Transformation—These days, with the rise of Common Core…

 
 

NEW: RI to Receive $1.2 Million from GlaxoSmithKline, LLC Suit

Thursday, November 15, 2012

 

Attorney General Peter F. Kilmartin announced today that he and 37 other Attorneys General reached a $90 million Consent Judgment with GlaxoSmithKline LLC (GSK) to resolve allegations that GlaxoSmithKline unlawfully promoted its diabetes drug, Avandia®. Rhode Island will receive approximately $1,243,000 from the settlement. Kilmartin alleges that GlaxoSmithKline engaged in unfair and deceptive practices by misrepresenting Avandia’s cardiovascular risks and safety profile.

“Time and time again, pharmaceutical companies ignore consumer protection laws, make claims not supported by clinical experience, and misrepresent information, all in the name of racking up steep profits,” said Attorney General Kilmartin. “This year alone, the Office has secured more than $5 million from pharmaceutical companies who engaged in deceptive marketing practices, and we will continue to go after those companies who refuse to play by the rules.”

As part of the Consent Judgment, GlaxoSmithKline agreed to reform how it markets and promotes diabetes drugs. Under the Consent Judgment, GSK may not:

  • Make any false, misleading, or deceptive claims about any diabetes drug;
  • Make comparative safety claims not supported by substantial evidence or substantial clinical experience;
  • Present favorable information previously thought of as valid but rendered invalid by contrary and more credible recent information;
  • Promote investigational drugs; or
  • Misuse statistics or otherwise misrepresent the nature, applicability, or significance of clinical trials.

The Consent Judgment also has the following terms that are effective for at least eight years:

  • GSK must post summaries of all GSK-sponsored observational studies or meta-analyses conducted by GSK that are designed to inform the effective, safe, and/or appropriate use of its diabetes drugs;
  • GSK shall post summaries of GSK-sponsored clinical trials of diabetes products within eight months of the primary completion date;
  • GSK shall register and post all GSK-sponsored clinical trials as required by federal law; and
  • GSK shall comply with the ICMJE Uniform Requirements for Manuscripts submitted to Biomedical Journals.
 

Enjoy this post? Share it with others.

 
 
:)